caa a22 4500 445331402 CHVBK 20180317142738.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10689-011-9418-1 doi (NATIONALLICENCE)springer-10.1007/s10689-011-9418-1 A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges [Elektronische Daten] [Molly Daniels, Jennifer Burzawa, Amanda Brandt, Kathleen Schmeler, Karen Lu] 10-15% of invasive epithelial ovarian cancer is attributable to hereditary breast and ovarian cancer. The identification of BRCA1/BRCA2 mutations in women with ovarian cancer allows for accurate predictive genetic testing of their at-risk relatives, who can then avail themselves of early detection and risk reduction strategies. In the case of women with recurrent progressive ovarian cancer, the window of opportunity for genetic testing can be particularly limited. Here we describe our perspective on providing genetic counseling during these patients' end of life care, incorporating two illustrative examples from our clinical practice. While these situations pose unique challenges, they also present a significant opportunity to benefit the patient and her family. Further attention and research should be directed towards provision of genetic counseling and testing during end of life care. Springer Science+Business Media B.V., 2011 Ovarian cancer nationallicence BRCA1 nationallicence BRCA2 nationallicence Genetic testing nationallicence Genetic counseling nationallicence Recurrent cancer nationallicence End of life issues nationallicence Daniels Molly U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut Burzawa Jennifer U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut Brandt Amanda U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut Schmeler Kathleen U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut Lu Karen U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut Familial Cancer Springer Netherlands 10/2(2011-06-01), 193-197 1389-9600 10:2<193 2011 10 10689 https://doi.org/10.1007/s10689-011-9418-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10689-011-9418-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Daniels Molly U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut NATIONALLICENCE 700 1- Burzawa Jennifer U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut NATIONALLICENCE 700 1- Brandt Amanda U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut NATIONALLICENCE 700 1- Schmeler Kathleen U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut NATIONALLICENCE 700 1- Lu Karen U.T.M.D. Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, 77230-1439, Houston, TX, USA aut NATIONALLICENCE 773 0- Familial Cancer Springer Netherlands 10/2(2011-06-01), 193-197 1389-9600 10:2<193 2011 10 10689 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer